Literature DB >> 27908264

Hypoxia and Inflammation in Prostate Cancer Progression. Cross-talk with Androgen and Estrogen Receptors and Cancer Stem Cells.

Matteo Antonio Russo1, Linda Ravenna, Laura Pellegrini, Elisa Petrangeli, Luisa Salvatori, Thea Magrone, Massimo Fini, Marco Tafani.   

Abstract

Tumors are complex tissues in which transformed cells communicate with the surrounding microenvironment and evolve traits promoting their own survival and malignancy. Hypoxia and inflammation are constant characteristics of prostate tumor microenvironment influencing both cancer stem cells and differentiated tumor cells. HIFs and NF-kB are the key regulators of the transcriptional response to hypoxic and inflammatory stresses, respectively, and a crosstalk between HIFs and NF-kB pathways has been widely documented. Similarly, androgen and estrogen signaling, that play important roles in the growth and function of normal prostate gland, when deregulated, have a significant part in the acquisition of hallmarks of malignant diseases. Moreover, androgen and estrogen receptors have been shown to intersect with the HIF/NF-kB signaling in prostate cancer. Aim of this review is to present the current knowledge regarding the crucial role, in prostate cancer progression, of a molecular network linking hypoxia, pro-inflammatory response and steroid receptors. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Androgen and estrogen receptors; cancer stem cells; hypoxia; inflammation; molecularzzm321990rehabilitation.; prostate cancer

Mesh:

Substances:

Year:  2016        PMID: 27908264     DOI: 10.2174/1871530316666161130160144

Source DB:  PubMed          Journal:  Endocr Metab Immune Disord Drug Targets        ISSN: 1871-5303            Impact factor:   2.895


  7 in total

Review 1.  High altitude exposure affects male reproductive parameters: could it also affect the prostate?†.

Authors:  Diana Elizabeth Alcantara-Zapata; Aníbal J Llanos; Carolina Nazzal
Journal:  Biol Reprod       Date:  2022-03-19       Impact factor: 4.285

Review 2.  Inflammation in Prostatic Hyperplasia and Carcinoma-Basic Scientific Approach.

Authors:  Božo Krušlin; Davor Tomas; Tihana Džombeta; Marija Milković-Periša; Monika Ulamec
Journal:  Front Oncol       Date:  2017-04-25       Impact factor: 6.244

3.  Assessment of biochemical recurrence of prostate cancer (Review).

Authors:  Xiaozeng Lin; Anil Kapoor; Yan Gu; Mathilda Jing Chow; Hui Xu; Pierre Major; Damu Tang
Journal:  Int J Oncol       Date:  2019-10-04       Impact factor: 5.650

4.  Characterization of Hormone-Dependent Pathways in Six Human Prostate-Cancer Cell Lines: A Gene-Expression Study.

Authors:  Andras Franko; Lucia Berti; Alke Guirguis; Jörg Hennenlotter; Robert Wagner; Marcus O Scharpf; Martin Hrabĕ de Angelis; Katharina Wißmiller; Heiko Lickert; Arnulf Stenzl; Andreas L Birkenfeld; Andreas Peter; Hans-Ulrich Häring; Stefan Z Lutz; Martin Heni
Journal:  Genes (Basel)       Date:  2020-10-07       Impact factor: 4.096

Review 5.  Selective estrogen receptor modulators contribute to prostate cancer treatment by regulating the tumor immune microenvironment.

Authors:  Dali Tong
Journal:  J Immunother Cancer       Date:  2022-04       Impact factor: 13.751

6.  The PCAT3/PCAT9-miR-203-SNAI2 axis functions as a key mediator for prostate tumor growth and progression.

Authors:  Fangfang Tao; Xinxin Tian; Zhiqian Zhang
Journal:  Oncotarget       Date:  2018-01-12

7.  Transcript Levels of Aldo-Keto Reductase Family 1 Subfamily C (AKR1C) Are Increased in Prostate Tissue of Patients with Type 2 Diabetes.

Authors:  Andras Franko; Lucia Berti; Jörg Hennenlotter; Steffen Rausch; Marcus O Scharpf; Martin Hrabĕ de Angelis; Arnulf Stenzl; Andreas L Birkenfeld; Andreas Peter; Stefan Z Lutz; Hans-Ulrich Häring; Martin Heni
Journal:  J Pers Med       Date:  2020-09-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.